300595
Third-party billing for public health STD services: A summary of coordinated needs assessment results
An assessment was sent from ten regional TTACs to STD-certified 340B clinics and agencies with a response rate of 72%. Data from each region was compiled into a national data set and analyzed in SAS 9.1.
Results were compiled from 333 responses representing 1,935 individual clinics. Less than one half (45%) of clinics were billing both Medicaid and third-party payers; 30% of clinics were billing Medicaid only, and one quarter (25%) of clinics were not billing either. Clinics that were not billing were smaller; more likely to provide STD services only; and more likely to be Health Department STD clinics.
There were over 1,000 clinics not billing third-party payers. The barriers identified through the assessment include: policies, confidentiality concerns, lack of staffing resources, and lack of infrastructure resources.
Learning Areas:
Administration, management, leadershipConduct evaluation related to programs, research, and other areas of practice
Public health or related public policy
Learning Objectives:
Describe the capacity for billing Medicaid and private third-party payers among clinics providing publicly-funded STD services;
Describe the characteristics of clinics with capacity for billing and those without;
List at least 3 potential barriers to billing for STD service sites.
Keyword(s): STDs/STI, Needs Assessment
Qualified on the content I am responsible for because: I am the project director of the Region I STD-related Reproductive Health Training and Technical Assistance Center funded by CDC to provide billing training and TA, and we led the nationally coordinated needs assessment,conducted data analysis, and are authors of the needs assessment summary report. I have worked with the Infertility Prevention Project and assessed STD-related systemic needs since 2004.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.